Researchers sought to determine whether subcutaneous isatuximab would be an effective treatment for patients with RRMM.

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how pharmacokinetic equivalency across varied patient weights supports flat dosing, ...

Sometimes, the best way to achieve a big outcome is to start small. That principle is at the center of new work from a University of Virginia researcher who specializes in nanotechnology and ...

Subcutaneous vedolizumab dose intensification restored steroid-free clinical response in approximately one-third of patients with IBD.

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who ...